NCT06300476View on ClinicalTrials.gov

Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2029

Conditions
Stargardt Disease 1
Interventions
GENETIC

JWK006

Subretinal administration of gene therapy vector JWK006 to one eye.

Trial Locations (1)

610044

West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER

NCT06300476 - Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1) | Biotech Hunter | Biotech Hunter